STAT6 and myeloid sarcoma: Indeed, differences in the weight of the JAG1–IL4, IL12A–STAT6 and PTPRC–JAG1 interactions in treated or untreated MS patients compared with HC would suggest that IFN-ß treatment has no effect on these pathways and as such, they may be considered as novel therapeutic targets.